Search results
Showing 16 to 30 of 31 results for erlotinib
Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.
Discontinued Reference number: GID-TA11206
Discontinued Reference number: GID-TA11207
In development Reference number: GID-TAG388 Expected publication date: TBC
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
In development Reference number: GID-TA10899 Expected publication date: TBC
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults.
Past technology appraisal appeals and decisions
Discontinued Reference number: GID-TAG422
Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
Erlotinib for the treatment of non-small-cell lung cancer (TA162)
This guidance has been updated and replaced by NICE technology appraisal guidance 374.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.
Discontinued Reference number: GID-TA11289